What We're Reading: Page 380
Industry reads hand-picked by our editors
Feb 11, 2015
Feb 10, 2015
-
Reuters
A faster cure? Achillion med mixed with Sovaldi clears hep C in just 6 weeks
-
-
FDA warning for blockbuster hopeful edoxaban hits Daiichi where it hurts
-
Roche's blockbuster Lucentis nabs fourth FDA approval
-
Pfizer may still be hungry after Hospira deal
-
FDA proposes new consumer-friendly print drug ad guidance
-
-
Arkansas settles Vertex Medicaid suit over pricey Kalydeco
-
-
Passing the torch: Ralph Neas' tenure at the Generic Pharmaceutical Association
Feb 09, 2015
Feb 06, 2015
-
Merck's hep C treatment loses FDA breakthrough status
-
-
-
Promising Roche Parkinson's med causes lung toxicity in monkey trials
-
-
-
U.S. Chamber knocks IP laggards India, Indonesia, Thailand and Vietnam in Asia
-
Pfizer on fire with early FDA nod for blockbuster Ibrance, $15B Hospira buyout
-
Study: Drug makers fail to meet adverse-event reporting requirements
-
Trans-Pacific Partnership trade talks fail to resolve patent & IP issues
Feb 05, 2015
-
UPDATE: Why Gilead's shares are tumbling despite stellar Q4 earnings
-
Earnings roundup: Merck tops expectations, steady GSK rises on ViiV IPO talk
-
-
US to launch large-scale universal flu shot testing in 2016
-
-
-
-
Moody's: Patent-cliff challenges will continue to dog big pharma
-
Merck's Belsomra for insomnia now available in US
-
Another FDA warning letter for India-based Apotex
Feb 04, 2015
-
UPDATE: Obama budget proposes historic, direct Medicare drug price negotiations
-
-
FTC: Ranbaxy must sell acne drug to Torrent Pharma before Sun takeover
-
-
Sanofi finally launches Afrezza inhaled insulin in the US
-
-
Chimerix shifts from Ebola focus to adenoviruses, CMV as outbreak wanes
-
Ireland threatens to cap drug prices
-
-
FDA approves new Zohydro ER pankiller formulation
Previous
